Researchers from the Massachusetts Institute of Technology (MIT) Jameel Clinic for Machine Learning in Health have announced the open-source release of Boltz-2, which now predicts molecular binding ...

Rapid, structure-free binding affinity prediction enables OpenFold3 to address key bottleneck in commercial early-stage drug discovery PALO ALTO, Calif., Jan. 20, 2026 /PRNewswire/ -- SandboxAQ today ...

AI therapeutics company built on causal biology, today announced the acquisition of CombinAbleAI and the launch of insitro's TherML™ (Therapeutic Machine Learning) platform. The acquisition, which is ...

Boltz-2 is the first biomolecular co-folding model to combine structure and binding affinity prediction, approaching the accuracy of physics-based free energy perturbation (FEP) calculations but at ...

Avner Schlessinger, PhD, right, working with his lab researchers at Mount Sinai AI Small Molecule Drug Discovery Center in New York City. [Mount Sinai] Most breakthrough discoveries are made based on ...

Drug discovery is a complex field that demands rigorous testing and comprehensive data analysis to ensure potential drug candidates can advance to clinical trials. One critical step is screening for ...

Researchers at the Massachusetts Institute of Technology and Recursion Pharmaceuticals Inc. have released an open-source AI model that can predict the binding strength of small molecules as well as ...

AI drug discovery startup Converge Bio raised $25 million in a Series A led by Bessemer Venture Partners, with additional backing from executives at Meta, OpenAI, and Wiz.

The ability to alter proteins to refine control over binding affinity and specificity can create tailored therapeutics with reduced side effects, highly sensitive diagnostic tools, efficient ...

Thought LeadersEdoardo FabiniPrincipal Scientist Evotec U.K. G-protein-coupled receptors (GPCRs) play a pivotal role in cellular signaling and have long been a major focus in drug discovery. These ...